JERUSALEM, Israel, August 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that its abstract, entitled "Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Five Oral Insulin Formulations in Healthy Subjects," has been chosen for presentation at the upcoming 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome, highlighting the successful results from its oral insulin trials on healthy volunteers.
Oramed's poster has been assigned presentation number PS 093 New Treatments and is available for viewing throughout the conference. Oramed's Chief Scientific Officer, Dr. Miriam Kidron, and Dr. Ehud Arbit, Oramed's Director of Research and Development, will present the poster on Tuesday Sept. 9, 2008, from 12:30 p.m. to 1:30 p.m.
"The fact that Oramed has been selected to present research at the EASD Conference underscores the importance of our work developing an oral insulin capsule," said Nadav Kidron, Oramed CEO. "We look forward to sharing the results of our Phase 1B trials with top diabetes researchers from around the world."
For more information about the EASD and the upcoming conference, please visit http://www.easd.org.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the
risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays
in obtaining regulatory approval for our product candidates; competition
from other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a comprehensive
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Ruder Finn Israel for Oramed
|SOURCE Oramed Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved